市場調查報告書

全球數位生物標記市場:主要趨勢、成長的潛在性、競爭情形 - 分析與市場預測 (2019-2025年)

Global Digital Biomarkers Market: Focus on Key Trends, Growth Potential, Competitive Landscape, Components, End Users, Application and Region - Analysis and Forecast, 2019-2025

出版商 BIS Research Inc. 商品編碼 919278
出版日期 內容資訊 英文 433 Pages
商品交期: 最快1-2個工作天內
價格
全球數位生物標記市場:主要趨勢、成長的潛在性、競爭情形 - 分析與市場預測 (2019-2025年) Global Digital Biomarkers Market: Focus on Key Trends, Growth Potential, Competitive Landscape, Components, End Users, Application and Region - Analysis and Forecast, 2019-2025
出版日期: 2020年03月12日內容資訊: 英文 433 Pages
簡介

全球數位生物標記的市場規模在2019年∼2025年的預測期間內,預計將以40.39%的年複合成長率發展。

全球數位生物標記市場上最大的治療市場區隔是心血管疾病市場區隔,佔市場31.75%的佔有率,其次是神經退化性疾病佔20.63%的佔有率。本報告在預測期間內,預測疼痛管理,心情、行動 (精神疾病) 市場區隔,記錄各為59.07%和45.34%的高年複合成長率。疼痛管理市場區隔的成長,主要是慢性疼痛的檢測和治療用AR / VR解決方案的開發與採用增加事項。

本報告涵括全球數位生物標記市場,提供市場動態,競爭環境,各市場區隔、各地區的市場,競爭情形,及主要企業等相關的詳細分析。

第1章 產品定義

第2章 調查範圍

第3章 調查手法

第4章 數位生物標記:全球展望

  • 定義
  • 數位生物標記的現狀
  • 數位生物標記的生態系統
    • 數位平台
  • 資料檢測
    • 生理的參數
    • 行動參數
  • 生物標記的種類
    • 健康
    • 疾病
    • 醫藥品
  • 產業
    • 製藥
    • 生物科技/生命科學
    • 應用程式供應商
    • 臨床實驗 (CRO)
    • 技術供應商
  • 數位生物標記:技術形勢
    • AI、機器學習
    • AR、VR
    • 區塊鏈
    • 邊緣運算
    • 雲端運算
  • 成功案例的案例研究:主要的治療領域
    • 心血管疾病
    • 阿茲海默症
    • 亨丁頓舞蹈症

第5章 市場動態

  • 成長促進因素
  • 市場課題
  • 市場機會

第6章 競爭情形

  • 概要
  • 主要的發展、策略
  • 競爭基準

第7章 數位生物標記市場機會、成長率

  • 資料收集
    • 穿戴式設備
  • 包含植/攝取可能的生物感應器
  • 行動/平板電腦應用程式
  • 資料整合
  • 全球數位生物標記市場:各用途
    • 腸胃疾病
    • 睡眠、運動
    • 心血管
    • 心情、行動 (精神疾病)
    • 慢性疼痛
    • 神經退化性疾病
    • 糖尿病
    • 呼吸狀態
    • 其他

第8章 全球數位生物標記市場:各終端用戶

  • 生物醫藥品企業
  • 保險者
  • 提供者

第9章 全球數位生物標記市場:各地區

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 荷蘭
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 俄羅斯
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 新加坡
    • 其他
  • 南美
    • 巴西
    • 墨西哥
  • 其他 (RoW)
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非

第10章 企業簡介

  • 概要
  • ActiGraph, LLC
  • Akili Interactive Labs
  • AliveCor Inc.
  • Altoida AG
  • Amgen Inc
  • Bayer AG
  • Biogen Inc.
  • Eli Lilly and Company
  • Evidation Health, Inc.
  • F. Hoffmann-La Roche Ltd
  • Fitbit, Inc.
  • GlaxoSmithKline Plc
  • Human API
  • Happify Health
  • IXICO Plc
  • Koninklijke Philips N.V.
  • Medopad Ltd
  • Mindstrong Health
  • Neurotrack Technologies, Inc.
  • Novartis International AG
  • Orikami
  • Pfizer Inc.
  • Quanterix Corporation
  • Sanofi S.A.
  • 武田藥品工業
  • Verily Life Sciences
  • Cambridge Cognition Plc
  • MC10 Inc.
  • Medical Care Corporation
  • Shimmer
  • Winterlight Labs Inc.

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BH174A

Global Digital Biomarkers Market to Grow at a CAGR of 40.39% from 2019-2025

Key Questions Answered in the Report:

  • What is the total addressable market (TAM) and the potential market opportunity for the global digital biomarkers market?
  • What are the major market drivers and challenges of, and the opportunities in, the global digital biomarkers market?
  • What is the market share of the leading segments and sub-segments of the global digital biomarkers market in 2019 and 2025?
  • How did the global digital biomarkers market evolve?
  • How is each segment of the global digital biomarkers market expected to grow during the forecast period and what is the expected revenue to be generated by each of the segments by the end of 2025?
  • What are the consumer preferences in terms of adoption of wearable technology for the assessment of medical conditions?
  • What are the key developmental strategies implemented by the key players to stand out in this market?
  • What is the preferred business model used for building digital biomarkers?
  • Which area of application is expected to be the highest revenue generator in the global digital biomarkers market during the forecast period?
  • Which end user segment is expected to be the highest revenue generator in this industry during the forecast period?
  • What is the potential of global digital biomarkers market in the emerging countries during the forecast period?

Global Digital Biomarkers Market Forecast, 2019-2025

The Global Digital Biomarkers Market Report by BIS Research projects the market to grow at a significant CAGR of 40.39% during the forecast period from 2019 to 2025. There are multiple factors that drive the market, such as the surge in the demand for mobile health apps and consumer wearable technology specifically for tracking health. For instance, as of 2019, about 35% of the U.S. adult population (18 to 29 years) track their health with the help of mobile apps while 27% of the adults own and use a wearable device for monitoring heart rate, blood pressure, physical activity, or other vitals.

Furthermore, the data generated from wearable devices are increasingly being validated through studies based on clinical trials. For instance, the number of clinical trials conducted using wearable devices was consistent during the period of 2008 to 2018, i.e. 5-12 trials annually. However, the number surged significantly in 2016 and 2017, with 27 and 32 trials (using mobile devices) commencing each year respectively. The primary reason for this rise in such trials in 2016 and 2017 can be attributed to the considerable surge in the sponsorship for these studies.

Expert Quote

"Cardiovascular disease segment is currently the largest therapeutic segment for the global digital biomarkers market and holds a share of 31.75% of the market, followed by neurodegenerative diseases with a share of 20.63%. During the forecast period, pain management, and mood and behavior segments, are expected to witness the highest CAGR of 59.07% and 45.34%, respectively. The growth in the pain management segment is primarily due to increasing development and adoption of AR/VR solutions for the detection and treatment of chronic pain."

Scope of the Market Intelligence on Global Digital Biomarkers Market

The purpose of this study is to gain a holistic view of the global digital biomarkers market in terms of various influencing factors such as regional adoption trends, technological advancements, and pricing patterns.

The scope of this report constitutes an in-depth study of the global digital biomarkers market, including a thorough analysis of the products in the market as well as their adoption spanning different regions. The market has been chiefly segmented into component, application, end user, and region. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

Market Segmentation

The Global Digital Biomarkers Market can be segmented on the basis of component type, application, end user, and region. As of 2018, biopharma companies held an estimated 57% of the global digital biomarkers market. Numerous collaborations and partnerships were witnessed in 2017 and 2018, aimed at developing digital solutions for the clinical assessment various disorders such as cardiovascular, neurodegenerative, and respiratory. Some of the notable biopharma companies engaging in partnership activities include, Takeda, Biogen, and Sanofi among others. A significant contribution was also witnessed from healthcare providers, who held an estimated 42% of the global digital biomarkers market in 2018.

During the forecast period (2019-2025), the health insurance payers are expected to evolve as the largest end user segmented in the global digital biomarkers market. The growth rate for this segment is expected to be 44.04% during the forecast period. This high growth rate is primarily due to an increasing use of digital biomarkers by payer groups to effectively devise individualized care plans.

In terms of region, Asia-Pacific is the largest market in the digital biomarkers space and is expected to remain same during the forecast period. North America is also contributing to the growth of this space. The elevated level of smartphone and wearable technology in these regions as well as the high incidence of lifestyle-related diseases are pushing consumers in the region to monitor their medical conditions.

However, during the forecast period, Europe is expected to attain the highest CAGR of 41.99%. The growth is primarily due to increasing standardization and collaboration among key stakeholders in the industry.

Key Companies in the Global Digital Biomarkers Market

Some of the major key players in the global digital biomarkers market include ActiGraph, LLC., Akili Interactive Labs, AliveCor, Inc., Fitbit, Inc., HumanAPI, Novartis, Pfizer Inc. F. Hoffmann-La Roche Ltd, Sanofi, Takeda Pharmaceuticals, and Verily Life Science LLC.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Products Considered

2 Scope of the Report

3 Research Methodology

  • 3.1 Global Digital Biomarkers Market: Research Methodology
    • 3.1.1 Primary Data Sources
    • 3.1.2 Secondary Data Sources

4 Digital Biomarkers: Global Perspective

  • 4.1 Definition
  • 4.2 Current State of Digital Biomarkers
  • 4.3 Digital Biomarkers Ecosystem
    • 4.3.1 Digital Platforms
      • 4.3.1.1 Wearables Devices
      • 4.3.1.2 Implantable Components/Sensors
      • 4.3.1.3 Ingestible Sensors
      • 4.3.1.4 Ocular Devices
      • 4.3.1.5 Accelerometers
      • 4.3.1.6 Smart Home Systems/IOTs
      • 4.3.1.7 AR/VR Platforms
      • 4.3.1.8 Desktop/Web Apps
  • 4.4 Data Measurements
    • 4.4.1 Physiological Parameters
    • 4.4.2 Behavioral Parameters
  • 4.5 Types of Biomarkers
    • 4.5.1 Wellness
    • 4.5.2 Disease
    • 4.5.3 Drugs
  • 4.6 Industry
    • 4.6.1 Pharmaceutical
    • 4.6.2 Biotechnology/Life Sciences
    • 4.6.3 Medical Devices
    • 4.6.4 App Vendors
    • 4.6.5 Clinical Trials (Clinical Research Organizations)
    • 4.6.6 Technology Vendors
  • 4.7 Digital Biomarkers: Technology Landscape
    • 4.7.1 Artificial Intelligence and Machine Learning
    • 4.7.2 Augmented Reality and Virtual Reality
    • 4.7.3 Blockchain
    • 4.7.4 Edge Computing
    • 4.7.5 Cloud Computing
  • 4.8 Successful Case Studies: Key Therapeutic Areas
    • 4.8.1 Cardiovascular Disease
    • 4.8.2 Parkinson's Disease
    • 4.8.3 Alzheimer's Disease
    • 4.8.4 Huntington's disease

5 Market Dynamics

  • 5.1 Growth Promoting Factors
    • 5.1.1 Explosion of Wearable Devices and Increasing Smartphone Penetration
    • 5.1.2 Increasing Cost of Drug Development
    • 5.1.3 Failure of Drugs for Neurodegenerative Disorder
    • 5.1.4 Regulatory Flexibility Toward Digital Health Solutions
  • 5.2 Market Challenges
    • 5.2.1 Need for Standardized and Interoperable Solutions
    • 5.2.2 Difference or Inaccuracy in Data Measurements
    • 5.2.3 Lack of Integration and Interoperability Between Medical Records and User Generated Data
    • 5.2.4 Lack of Use Cases Pertaining to the Return on Investment (ROI) Analysis
  • 5.3 Market Opportunities
    • 5.3.1 Digital Biomarkers: The Future of Precision Medicine
    • 5.3.2 Investment in Voice-Based Digital Biomarkers
    • 5.3.3 Investment in Wearable Technology
      • 5.3.3.1 Early Detection of Neurological Disorders
      • 5.3.3.2 For General Health Management
      • 5.3.3.3 Metabolic, Cardiovascular, and Gastrointestinal Health
      • 5.3.3.4 Maternal, Pre- and Neo-Natal Care
      • 5.3.3.5 Pulmonary Health and Environmental Exposures

6 Competitive Landscape

  • 6.1 Key Strategies and Developments
    • 6.1.1 Synergistic Interactions
    • 6.1.2 Product Launches and Enhancements
    • 6.1.3 Business Expansion and Funding Activities
    • 6.1.4 Acquisitions, Approvals, and Others

7 Digital Biomarker Market Opportunities and Growth, 2018-2025 ($Million)

  • 7.1 Data Collection (Sensors and Tools that Collect Data)
    • 7.1.1 Wearables Devices
      • 7.1.1.1 Evolution of Wearable Devices in Clinical Trials
      • 7.1.1.2 Wearable Devices in Clinical Trials
      • 7.1.1.3 Actigraphy Devices
        • 7.1.1.3.1 Generational Change from Polysomnography to Actigraphy
        • 7.1.1.3.2 ActiGraph
      • 7.1.1.4 Market Estimation and Forecast, 2018-2025
      • 7.1.1.5 Opportunity in Digital Biomarker
      • 7.1.1.6 New Developments
  • 7.2 Implantable/Ingestible Biosensors
    • 7.2.1 Market Estimation and Forecast, 2018-2025
    • 7.2.2 Opportunity in Digital Biomarker
  • 7.3 Mobile/Tablet Apps
    • 7.3.1 Market Estimation and Forecast, 2018-2025
    • 7.3.2 Opportunity in Digital Biomarker
    • 7.3.3 New Developments
    • 7.3.4 Competitive Landscape
  • 7.4 Data Integration
    • 7.4.1 Market Estimation and Forecast, 2018-2025
    • 7.4.2 Competitive Landscape
  • 7.5 Global Digital biomarkers Market (by Application)
    • 7.5.1 Gastrointestinal Diseases
      • 7.5.1.1 Inflammatory Bowel's Disease
    • 7.5.2 Sleep and Movement
    • 7.5.3 Cardiovascular
    • 7.5.4 Mood and Behavior (Psychiatric Disorders)
    • 7.5.5 Chronic Pain
    • 7.5.6 Neurodegenerative Disorders
      • 7.5.6.1 Parkinson's Disease
      • 7.5.6.2 Multiple Sclerosis
      • 7.5.6.3 Alzheimer's Disease
    • 7.5.7 Diabetes
    • 7.5.8 Respiratory Conditions
    • 7.5.9 Others

8 Global Digital Biomarkers Market, by End Users

  • 8.1 Biopharmaceutical Companies
    • 8.1.1 Role of Biopharma Companies in the Development of Digital Biomarkers
    • 8.1.2 Major Therapeutic Areas for Biomarkers
      • 8.1.2.1 Respiratory Diseases
      • 8.1.2.2 Neurodegenerative Diseases
      • 8.1.2.3 Cardiovascular Diseases
      • 8.1.2.4 Diabetes
  • 8.2 Payers
  • 8.3 Providers

9 Global Digital Biomarkers Market (by Region)

  • 9.1 North America
    • 9.1.1 U.S
      • 9.1.1.1 Digital Health Scenario
      • 9.1.1.2 Degree of Adoption of Wearables
      • 9.1.1.3 Degree of Adoption of Mobile Health Applications
      • 9.1.1.4 Local Players in the Digital Biomarker Market
      • 9.1.1.5 Regulatory Scenario
    • 9.1.2 Canada
      • 9.1.2.1 Digital Health Scenario
      • 9.1.2.2 Degree of Adoption of Wearables
      • 9.1.2.3 Degree of Adoption of Mobile Health Applications Adoption
      • 9.1.2.4 Local Digital Biomarker Market
      • 9.1.2.5 Regulatory Scenario
      • 9.1.2.6 Future of Digital Health in Canada
  • 9.2 Europe
    • 9.2.1 Netherlands
      • 9.2.1.1 Digital Health Scenario
      • 9.2.1.2 Level of Wearables Adoption
      • 9.2.1.3 Degree of Adoption of Mobile Health Applications
      • 9.2.1.4 Local Players in the Digital Biomarker Market
    • 9.2.2 Germany
      • 9.2.2.1 Digital Health Scenario
      • 9.2.2.2 Degree of Adoption of Wearables
      • 9.2.2.3 Reluctance to Fitness Trackers
      • 9.2.2.4 Future of Digital Health in Germany
    • 9.2.3 U.K.
      • 9.2.3.1 Digital Health Scenario
      • 9.2.3.2 Degree of Adoption of Wearables
      • 9.2.3.3 Increasing Sales of Smartwatches
      • 9.2.3.4 Abandonment of Wearables
      • 9.2.3.5 Local Players in Wearables
    • 9.2.4 France
      • 9.2.4.1 Digital Health Scenario
      • 9.2.4.2 Degree of Wearables Adoption
      • 9.2.4.3 Local Players in Digital Biomarkers Market
    • 9.2.5 Spain
      • 9.2.5.1 Digital Health Scenario
      • 9.2.5.2 Degree of Adoption of Wearables
    • 9.2.6 Italy
      • 9.2.6.1 Digital Health Scenario
      • 9.2.6.2 Degree of Adoption of Wearables
      • 9.2.6.3 Degree of Adoption of Mobile Health Applications
    • 9.2.7 Russia
      • 9.2.7.1 Digital Health Scenario
      • 9.2.7.2 Degree of Adoption of Wearables
      • 9.2.7.3 Degree of Adoption of Mobile Health Applications
    • 9.2.8 Rest-of-Europe
      • 9.2.8.1 Digital Health Scenario
      • 9.2.8.2 Degree of Adoption of Wearables
      • 9.2.8.3 Degree of Adoption of Mobile Health Applications
      • 9.2.8.4 Local Player in Digital Biomarker Market
  • 9.3 Asia-Pacific
    • 9.3.1 China
      • 9.3.1.1 Digital Health Scenario
      • 9.3.1.2 Degree of Adoption of Wearables
      • 9.3.1.3 Degree of Adoption of Mobile Health Applications
      • 9.3.1.4 Local Players in Digital Biomarker Market
    • 9.3.2 Japan
      • 9.3.2.1 Digital Health Scenario
      • 9.3.2.2 Degree of Wearables Adoption
      • 9.3.2.3 Degree of Mobile Health Applications Adoption
      • 9.3.2.4 Local Players in Digital Biomarker Market
    • 9.3.3 South Korea
      • 9.3.3.1 Digital Health Scenario
      • 9.3.3.2 Degree of Adoption of Wearables
      • 9.3.3.3 Degree of Adoption of Mobile Health Applications
    • 9.3.4 India
      • 9.3.4.1 Digital Health Scenario
      • 9.3.4.2 Degree of Adoption of Wearables
      • 9.3.4.3 Degree of adoption of Mobile Health Applications
      • 9.3.4.4 Local Players in Digital Biomarker Market
    • 9.3.5 Australia
      • 9.3.5.1 Digital Health Scenario
      • 9.3.5.2 Level of Wearables Adoption
      • 9.3.5.3 Level of Mobile Health Applications Adoption
    • 9.3.6 Singapore
      • 9.3.6.1 Digital Health Scenario
      • 9.3.6.2 Degree of Adoption of Wearables
      • 9.3.6.3 Degree of Adoption of Mobile Health Applications
    • 9.3.7 Rest-of-Asia-Pacific
      • 9.3.7.1 Digital Health Scenario
      • 9.3.7.2 Degree of adoption of Wearables and Mobile Health Application
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Digital Health Scenario
      • 9.4.1.2 Degree of Adoption of Wearables
      • 9.4.1.3 Degree of Adoption of Mobile Health Applications
    • 9.4.2 Mexico
      • 9.4.2.1 Digital Health Scenario
      • 9.4.2.2 Degree of Adoption of Wearables
      • 9.4.2.3 Degree of Adoption of Mobile Health Applications
  • 9.5 Rest-of-the-World
    • 9.5.1 Saudi Arabia
      • 9.5.1.1 Digital Health Scenario
      • 9.5.1.2 Degree of Adoption of Wearables
      • 9.5.1.3 Degree of Adoption of Mobile Health Applications
    • 9.5.2 U.A.E.
      • 9.5.2.1 Digital Health Scenario
      • 9.5.2.2 Degree of Adoption of Wearables and Mobile Health Applications
    • 9.5.3 Israel
      • 9.5.3.1 Digital Health Scenario
      • 9.5.3.2 Degree of Adoption of Wearables
    • 9.5.4 South Africa
      • 9.5.4.1 Digital Health Scenario
      • 9.5.4.2 Degree of Adoption of Wearables
      • 9.5.4.3 Degree of Adoption of Mobile Health Applications

10 Company Profiles

  • 10.1 Overview
  • 10.2 ActiGraph, LLC
    • 10.2.1 Company Overview
    • 10.2.2 Role of ActiGraph, LLC in the Global Digital Biomarkers Market
    • 10.2.3 Recent Developments
    • 10.2.4 SWOT Analysis: ActiGraph, LLC
  • 10.3 Akili Interactive Labs
    • 10.3.1 Company Overview
    • 10.3.2 Role of Akili Interactive Labs in the Global Digital Biomarkers Market
    • 10.3.3 Recent Developments
    • 10.3.4 SWOT Analysis
  • 10.4 AliveCor Inc.
    • 10.4.1 Company Overview
    • 10.4.2 Role of AliveCor, Inc. in the Global Digital Biomarkers Market
    • 10.4.3 Recent Development
    • 10.4.4 SWOT Analysis
  • 10.5 Altoida AG
    • 10.5.1 Company Overview
    • 10.5.2 Role of Altoida AG in the Global Digital Biomarkers Market
    • 10.5.3 Recent Developments
    • 10.5.4 SWOT Analysis
  • 10.6 Amgen Inc
    • 10.6.1 Company Overview
    • 10.6.2 Role of Amgen Inc. in the Global Digital Biomarkers Market.
    • 10.6.3 Financials
    • 10.6.4 Key Insights About Financial Health of the Company
    • 10.6.5 Recent Developments
    • 10.6.6 SWOT Analysis
  • 10.7 Bayer AG
    • 10.7.1 Company Overview
    • 10.7.2 Role of Bayer AG in the Global Digital Biomarkers Market
    • 10.7.3 Financials
    • 10.7.4 Key Insights About Financial Health of the Company
    • 10.7.5 Recent Developments
    • 10.7.6 SWOT Analysis
  • 10.8 Biogen Inc.
    • 10.8.1 Company Overview
    • 10.8.2 Role of Biogen Inc. in the Global Digital Biomarkers Market
    • 10.8.3 Financials
    • 10.8.4 Key Insights About Financial Health of the Company
    • 10.8.5 Recent Developments
    • 10.8.6 SWOT Analysis
  • 10.9 Eli Lilly and Company
    • 10.9.1 Company Overview
    • 10.9.2 Role of Eli Lilly and Company in the Global Digital Biomarkers Market
    • 10.9.3 Financials
    • 10.9.4 Key Insights About Financial Health of the Company
    • 10.9.5 Recent Developments
    • 10.9.6 SWOT Analysis
  • 10.10 Evidation Health, Inc.
    • 10.10.1 Company Overview
    • 10.10.2 Role of Evidation Health, Inc. in the Global Digital Biomarker Market
    • 10.10.3 Recent Developments
    • 10.10.4 SWOT Analysis
  • 10.11 F. Hoffmann-La Roche Ltd
    • 10.11.1 Company Overview
    • 10.11.2 Role of F. Hoffmann-La Roche Ltd in the Global Digital Biomarkers Market
    • 10.11.3 Financials
    • 10.11.4 Key Insights About Financial Health of the Company
    • 10.11.5 Recent Developments
    • 10.11.6 SWOT Analysis
  • 10.12 Fitbit, Inc.
    • 10.12.1 Company Overview
    • 10.12.2 Role of Fitbit Inc. in the Global Digital Biomarker Market
    • 10.12.3 Financials
    • 10.12.4 Key Insights About Financial Health of the Company
    • 10.12.5 Recent Developments
    • 10.12.6 SWOT Analysis
  • 10.13 GlaxoSmithKline Plc
    • 10.13.1 Company Overview
    • 10.13.2 Role of GlaxoSmithKline Plc in the Global Digital Biomarkers Market
    • 10.13.3 Financials
    • 10.13.4 Key Insights About Financial Health of the Company
    • 10.13.5 Recent Developments
    • 10.13.6 SWOT Analysis
  • 10.14 Human API
    • 10.14.1 Company Overview
    • 10.14.2 Role of Human API in the Global Digital Biomarkers Market
    • 10.14.3 Recent Developments
    • 10.14.4 SWOT Analysis
  • 10.15 Happify Health
    • 10.15.1 Company Overview
    • 10.15.2 Role of Happify Health in the Global Digital Biomarker Market
    • 10.15.3 Recent Developments
    • 10.15.4 SWOT Analysis
  • 10.16 IXICO Plc
    • 10.16.1 Company Overview
    • 10.16.2 Role of IXICO Plc in the Global Digital Biomarkers Market
    • 10.16.3 Financials
    • 10.16.4 Key Insights About Financial Health of the Company
    • 10.16.5 Recent Developments
    • 10.16.6 SWOT Analysis
  • 10.17 Koninklijke Philips N.V.
    • 10.17.1 Company Overview
    • 10.17.2 Role of Koninklijke Philips N.V. in the Global Digital Biomarkers Market
    • 10.17.3 Financials
    • 10.17.4 Key Insights About Financial Health of the Company
    • 10.17.5 Recent Developments
    • 10.17.6 SWOT Analysis
  • 10.18 Medopad Ltd
    • 10.18.1 Company Overview
    • 10.18.2 Role of Medopad Ltd in the Global Digital Biomarker Market
    • 10.18.3 Recent Developments
    • 10.18.4 SWOT Analysis
  • 10.19 Mindstrong Health
    • 10.19.1 Company Overview
    • 10.19.2 Role of Mindstrong Health in the Global Digital Biomarker Market
    • 10.19.3 Recent Developments
    • 10.19.4 SWOT Analysis
  • 10.20 Neurotrack Technologies, Inc.
    • 10.20.1 Company Overview
    • 10.20.2 Role of Neurotrack Technologies, Inc in the Global Digital Biomarker Market
    • 10.20.3 Recent Developments
    • 10.20.4 SWOT Analysis
  • 10.21 Novartis International AG
    • 10.21.1 Company Overview
    • 10.21.2 Role of Novartis International AG in the Global Digital Biomarkers Market
    • 10.21.3 Financials
    • 10.21.4 Key Insights About Financial Health of the Company
    • 10.21.5 Recent Developments
    • 10.21.6 SWOT Analysis
  • 10.22 Orikami
    • 10.22.1 Company Overview
    • 10.22.2 Role of Orikami in the Global Digital Biomarker Market
    • 10.22.3 Recent Developments
    • 10.22.4 SWOT Analysis
  • 10.23 Pfizer Inc.
    • 10.23.1 Company Overview
    • 10.23.2 Role of Pfizer Inc in the Global Digital Biomarkers Market
    • 10.23.3 Financials
    • 10.23.4 Key Insights About Financial Health of the Company
    • 10.23.5 Recent Developments
    • 10.23.6 SWOT Analysis
  • 10.24 Quanterix Corporation
    • 10.24.1 Company Overview
    • 10.24.2 Role of Quanterix Corporation in the Global Digital Biomarker Market
    • 10.24.3 Financials
    • 10.24.4 Key Insights About Financial Health of the Company
    • 10.24.5 Recent Developments
    • 10.24.6 SWOT Analysis
  • 10.25 Sanofi S.A.
    • 10.25.1 Company Overview
    • 10.25.2 Role of Sanofi S.A. in the Global Digital Biomarker Market
    • 10.25.3 Financials
    • 10.25.4 Key Insights About Financial Health of the Company
    • 10.25.5 Recent Developments
    • 10.25.6 SWOT Analysis
  • 10.26 The Takeda Pharmaceuticals Company Limited
    • 10.26.1 Company Overview
    • 10.26.2 Role of The Takeda Pharmaceuticals Company Limited in the Global Digital Biomarkers Market
    • 10.26.3 Financials
    • 10.26.4 Key Insights About Financial Health of the Company
    • 10.26.5 Recent Developments
    • 10.26.6 SWOT Analysis
  • 10.27 Verily Life Sciences
    • 10.27.1 Company Overview
    • 10.27.2 Role of Verily Life Sciences in the Global Digital Biomarkers Market
    • 10.27.3 Recent Developments
    • 10.27.4 SWOT Analysis: Verily Life Sciences
  • Company Snapshots
  • 10.28 Cambridge Cognition Plc
    • 10.28.1 Company Overview
    • 10.28.2 Role of Cambridge Cognition Plc. in the Global Digital Biomarkers Market
    • 10.28.3 Recent Developments
  • 10.29 MC10 Inc.
    • 10.29.1 Company Overview
    • 10.29.2 Role of MC10 Inc. in the Global Digital Biomarkers Market
    • 10.29.3 Recent Developments
  • 10.30 Medical Care Corporation
    • 10.30.1 Company Overview
    • 10.30.2 Role of Medical Care Corporation in the Global Digital Biomarkers Market
  • 10.31 Shimmer
    • 10.31.1 Company Overview
    • 10.31.2 Role of Shimmer in the Global Digital Biomarkers Market
    • 10.31.3 Recent Developments
  • 10.32 Winterlight Labs Inc.
    • 10.32.1 Company Overview
    • 10.32.2 Role of Winterlight Labs, Inc. in the Global Digital Biomarkers Market
    • 10.32.3 Recent Developments

List of Tables

  • Table 1: A Comparison Between Examples of Clinical Biomarkers and Digital Biomarkers
  • Table 2: Percentage of Different Wearable Technology Brands Being Used in Clinical Trials (As of December 2019, N=1600)
  • Table 3: Regional Perspective: From Consumer (Non-Clinical) Generated Data, $Million, 2018-2025
  • Table 4: Regional Perspective: Patient Centric Data During Clinical Trials, $Million, 2018-2025
  • Table 4.1: Different Categories of Mobile Health Applications
  • Table 5.1: Leading Wearable Devices and Their Features
  • Table 5.2: Major FDA Clearances in 2019
  • Table 6.1: Synergistic Activities Share (by Company), January 2016- September 2019
  • Table 6.2: Product Launches and Enhancements Share (by Company), January 2016 - September 2019
  • Table 6.3: Business Expansion and Funding Activities Share (by Company), January 2016 - September 2019
  • Table 6.4: Key Acquisitions in the global digital biomarkers Space (2019)
  • Table 7.4: Distribution of Clinical Trials Performed Using Wearable Connected Devices (Up to Dec 2019)
  • Table 7.5: ActiGraph Objective Measures
  • Table 7.6: Recent Key Developments in the Digital Biomarker Space in Terms of Wearable Devices
  • Table 7.7: Some of the recent developments in this segment
  • Table 7.9: Potential Digital Tools for the Measurement of Outcomes for Inflammatory Bowel's Disease
  • Table 7.10: Overview of Clinical Trials Performed Using Mobile Application for the Monitoring/Management of IBD
  • Table 7.11: Commercially Available Mobile Apps Used for the Monitoring and Management of Inflammatory Bowel's Disease
  • Table 7.14: Clinical Trials Using Mobile Application for the Assessment of Sleep-Related Disorders:
  • Table 7.15: Clinical Trials Using Wearable Devices for the Assessment of Sleep-Related Disorders
  • Table 7.16: Some of the key developments in the Field of Sleep Disorders Using Digital Health
  • Table 7.17: Overview of Clinical Trials Performed Using Mobile Application for the Monitoring/Management of Cardiovascular Diseases
  • Table 7.18: Overview of Clinical Trials Performed Using Wearable Devices for the Monitoring/Management of Cardiovascular Diseases
  • Table 7.19: Recent Developments Using Wearable Developments for the Assessment of Cardiovascular Diseases
  • Table 7.20: Clinical Trials Using Actigraphy devices for the Assessment of Mood Disorders
  • Table 7.22: Recent Developments in the Mood Related Disorders Space
  • Table 7.23: Number of Clinical Trials Using a Mobile Application, 2019
  • Table 7.24: Increased Use of Wearable Devices in Clinical Trials for Chronic Pain
  • Table 7.25: Recent Key Developments in the Field of Digital Tech Assisted Chronic Pain Management
  • Table 7.26: Top 5 Clinical Trials on Parkinson's Disease Conducted Using Smartphone Apps
  • Table 7.27: Some of the Clinical Trials on Parkinson's Disease Conducted Using Wearable Devices
  • Table 7.28: Top 5 Clinical Trials on Multiple Sclerosis Conducted Using Smartphone Apps
  • Table 7.29: Some of The Clinical Trials on Multiple Sclerosis Conducted Using Wearable Devices
  • Table 7.30: Top 5 Clinical Trials on Alzheimer's Disease Conducted Using Smartphone Apps
  • Table 7.31: Some of the Clinical Trials on Alzheimer's Disease Conducted Using Wearable Devices
  • Table 7.32: Recent Developments in the Neurodegenerative Disease Space Pertaining to Digital Biomarkers
  • Table 7.33: Clinical Trials Using Mobile Application for the Management of Diabetes:
  • Table 7.34: Clinical Trials Using Wearable Devices to Manage Diabetes
  • Table 7.35: Key Developments Involving Wearables/Mobile Application in the Management of Diabetes
  • Table 7.36: Leading Respiratory Conditions and Related Deaths
  • Table 7.37: Top 5 Clinical Trials on Respiratory Disease Conducted Using Mobile Apps
  • Table 7.38: Some of the Clinical Trials on Respiratory Disease Conducted Using Wearable Devices
  • Table 7.39: Recent Developments in the Respiratory Segment
  • Table 9.1: Different Types of Health Tracking People and Their Characteristics
  • Table 9.4: Rate of Usage of Wearables in Italy
  • Table 9.5: Different Classes of Mobile Application in Healthcare and their Rate of Usage (%)
  • Table 9.6: Different European Countries and the Level of Adoption of Consumer Wearables (in Percentage, 2019)
  • Table 9.7: Different Wearables and Their Adoption Rates in Australia
  • Table 9.8: Different Wearables and Their Expected Adoption Rates in Australia
  • Table 9.9: Different Wearables and Their Adoption Rates in Singapore
  • Table 9.10: Different Wearables and Their Expected Adoption Rates in Singapore
  • Table 9.11: Different Wearables and Their Adoption Rates in Mexico
  • Table 9.12: Different Wearables and Their Expected Adoption Rates in Singapore
  • Table 10.1: Clinical Trials Involving Devices from ActiGraph, LLC
  • Table 10.2: Akili Interactive Labs: Clinical Trials
  • Table 10.3: AliveCor, Inc.: Clinical Trials
  • Table 10.4: Altoida AG: Clinical Trials
  • Table 10.5: Bayer AG: Clinical Trial
  • Table 10.6: Biogen Inc.: Clinical Trial
  • Table 10.7: Eli Lilly and Company: Clinical Trials
  • Table 10.8: Evidation Health, Inc.: Clinical Trials
  • Table 10.9: F. Hoffmann-La Roche Ltd: Clinical Trials
  • Table 10.10: Fitbit, Inc.: Clinical Trials
  • Table 10.11: GlaxoSmithKline Plc: Clinical Trials
  • Table 10.12: Happify Health: Clinical Trials
  • Table 10.13: Koninklijke Philips N.V.
  • Table 10.14: Medopad Ltd: Clinical Trials
  • Table 10.15: Mindstrong Health: Clinical Trials
  • Table 10.16: Neurotrack Technologies, Inc.: Clinical Trials
  • Table 10.17: Novartis International AG: Clinical Trials
  • Table 10.18: Pfizer Inc: Clinical Trials
  • Table 10.19: Quanterix Corporation: Clinical Trials
  • Table 10.20: Verily Life Sciences: Projects
  • Table 10.21: Verily Life Sciences: Clinical Trials
  • Table 10.22: MC10 Inc: Clinical Trials
  • Table 10.23: Shimmer: Clinical Trials
  • Table 10.24: Winterlight Labs, Inc: Clinical Trials

List of Figures

  • Figure 1: Global Subscriber Base and Smartphone Penetration
  • Figure 2: Number of Clinical Trials Using Connected Wearable Devices by Year (Cumulative)
  • Figure 3: Percentage of Completed and Active Clinical Trials Using Wearables (As of December 2019, N=1600)
  • Figure 5: Global Digital Biomarkers Market (by Type), $Million, 2018-2025
  • Figure 6: Global Digital Biomarkers Market, Provider Type (Data Collection), $Million, 2018-2025
  • Figure 7: Global Digital Biomarkers Market, Data Collection System Type, $Million, 2018-2025
  • Figure 8: Global Digital Biomarkers Market, Data Integration System Providers, $Million, 2018-2025
  • Figure 9: Global Digital Biomarkers Market (Application/Therapeutic Area), $Million, 2018-2025
  • Figure 10: Share of Leading Therapeutic Areas in the Digital Biomarkers Market, 2018 and 2025 (Market Size: 2018 = $524.6 million, 2025 = $5.63 billion)
  • Figure 11: Global Digital Biomarkers Market (End Users), $Million, 2018-2025
  • Figure 12: Current Penetration of Different End User Groups in the Digital Biomarkers Market (2018)
  • Figure 2.1: Global Digital Biomarkers Market: Breakup of the Market
  • Figure 3.1: Global Digital Biomarkers Market Research Methodology
  • Figure 3.2: Primary Research
  • Figure 3.3: Secondary Research
  • Figure 3.4: Data Triangulation
  • Figure 3.5: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.6: Top-Down Approach (Segment-Wise Analysis)
  • Figure 3.7: Assumptions and Limitations
  • Figure 3.8: Considered Factors for Data Prediction and Modeling
  • Figure 3.9: Scope Definition for the Global Digital Biomarkers Market
  • Figure 4.1: Major Components of Digital Biomarkers Market
  • Figure 4.2: A Flowchart Depicting the Conversion of Healthcare Data to a Digital Biomarker
  • Figure 4.3: Different Populations of Data Producers of Digital Biomarkers
  • Figure 5.1: Number of Alzheimer's Disease Drug Under Development
  • Figure 6.1: Share of Key Developments and Strategies, January 2016-September 2019 (Total Developments = 106)
  • Figure 7.1: Global Digital Biomarker Data Collection Market ($million), 2018-2025
  • Figure 7.2: Wearable Devices and its Market Share (in Units) in Global Healthcare Sector
  • Figure 7.3: Clinical Trials Using Connected Wearable Devices by Year (Cumulative)
  • Table 7.1: Number of Clinical Trials Performed Using Different Brands of Wearables Catering to Diverse Therapeutic Areas (Cumulative, As of 2019)
  • Table 7.2: Distribution of Number of Clinical Trials Using Wearable Devices, by Country (Up to Dec 2019)
  • Table 7.3: A Comparative Analysis on the Commercially Available Actigraphy Devices
  • Figure 7.4: Distribution of Number of Clinical Trials Using Actigraphy Devices, by Region (Cumulative as of 2019)
  • Figure 7.5: Distribution of Number of Clinical Trials Using ActiGraph Devices, by Therapeutic Areas (Cumulative as of 2019)
  • Figure 7.6: Evolution of Four Generations of ActiGraph Activity Monitors
  • Figure 7.7: Global Wearable Devices Digital Biomarkers Market ($million), 2018-2025
  • Figure 7.8: Global Implantable Components/Biosensors Market, $Million, 2018-2025
  • Figure 7.9: Global Mobile/Tablet Apps Market, $Million, 2018-2025
  • Figure 7.10: Global Data Integration Systems Market, $Million, 2018-2025
  • Figure 7.11: Global Digital Biomarkers Market, Application Type: Gastrointestinal Diseases, $Million, 2018-2025
  • Figure 7.12: Global Digital Biomarkers Market, Application Type: Sleep Disorders, $Million, 2018-2025
  • Figure 7.13: Global Digital Biomarkers Market, Application Type: Cardiovascular, $Million, 2018-2025
  • Figure 7.14: Global Digital Biomarkers Market, Application Type: Mood and Behavior, $Million, 2018-2025
  • Figure 7.15: Global Digital Biomarkers Market, Application Type: Chronic Pain, $Million, 2018-2025
  • Figure 7.16: Global Digital Biomarkers Market, Application Type: Neurodegenerative Disorders, $Million, 2018-2025
  • Figure 7.17: Global Digital Biomarkers Market, Application Type: Respiratory Conditions, $Million, 2018-2025
  • Figure 7.18: Global Digital Biomarkers Market, Application Type: Respiratory Conditions, $Million, 2018-2025
  • Figure 7.19: Global Digital Biomarkers Market, Application Type: Other Therapeutic Areas, $Million, 2018-2025
  • Figure 8.1: Potential Use Cases of Digital Biomarkers (From an End User Perspective)
  • Figure 8.2: Global Digital Biomarkers Market, End User Type: Biopharma companies, $Million, 2018-2025
  • Figure 8.3: Global Digital Biomarkers Market, End User Type: Health Insurance Payers, $Million, 2018-2025
  • Figure 8.4: Global Digital Biomarkers Market, End User Type: Healthcare Providers, $Million, 2018-2025
  • Figure 9.1: North America Digital Biomarkers Market, Clinical Trials, $Million, 2018-2025
  • Figure 9.2: North America Digital Biomarkers Market, Non-Clinical, $Million, 2018-2025
  • Figure 9.3: Factors Influencing Digital Biomarkers Market in North America
  • Figure 9.4: U.S. Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.5: U.S. Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.6: Canada Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.7: Canada Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.8: Mobile Health Applications: Usage Areas (As of 2019)
  • Figure 9.9: Europe Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.10: Factors Influencing Digital Biomarkers Market in Europe
  • Figure 9.11: Netherlands Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.12: Netherlands Digital Biomarkers Market, by Settings, $Million, 2018-2025
  • Figure 9.13: Germany Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.14: Germany Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.15: U.K. Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.16: U.K. Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.17: France Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.18: France Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.19: Spain Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.20: Spain Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.21: Italy Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.22: Italy Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.23: Russia Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.24: Russia Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.25: Belgium Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.26: Sweden Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.27: Denmark Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.28: Norway Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.29: Asia-Pacific Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.30: Factors Influencing Digital Biomarkers Market in Asia-Pacific
  • Figure 9.31: China Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.32: China Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.33: Japan Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.34: Japan Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.35: South Korea Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.36: South Korea Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.37: India Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.38: India Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.39: Australia Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.40: Australia Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.41: Singapore Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.42: Latin America Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.43: Factors Influencing Digital Biomarkers Market in Latin America
  • Figure 9.44: Brazil Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.45: Brazil Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.46: Mexico Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.47: Mexico Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.48: Rest-of-the-World Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.49: Factors Influencing Digital Biomarkers Market in Rest-of-the-World
  • Figure 9.50: Saudi Arabia Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.51: Saudi Arabia Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.52: U.A.E. Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.53: U.A.E. Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.54: Israel Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.55: Israel Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 9.56: South Africa Digital Biomarkers Market, $Million, 2018-2025
  • Figure 9.57: South Africa Digital Biomarkers Market (by Setting), $Million, 2018-2025
  • Figure 10.1: Total Number of Companies Profiled
  • Figure 10.2: ActiGraph, LLC: Product Portfolio for the Global Digital Biomarkers Market
  • Figure 10.3: ActiGraph, LLC.: SWOT Analysis
  • Figure 10.4: Akili Interactive Labs: Product Portfolio for the Global Digital Biomarkers Market
  • Figure 10.5: Akili Interactive Labs: SWOT Analysis
  • Figure 10.6: AliveCor, Inc: Product Portfolio for the Global Digital Biomarkers Market
  • Figure 10.7: AliveCor Inc.: SWOT Analysis
  • Figure 10.8: Altoida, AG: Product Portfolio for the Global Digital Biomarkers Market
  • Figure 10.9: Altoida AG.: SWOT Analysis
  • Figure 10.10: Amgen Inc: Overall Financials, 2016-2018
  • Figure 10.11: Amgen Inc. Revenue (by Region), 2016-2018
  • Figure 10.12: Amgen Inc. R&D Expenditure, 2016-2018
  • Figure 10.13: Amgen Inc: SWOT Analysis
  • Figure 10.14: Bayer AG.: Overall Financials, 2016-2018
  • Figure 10.15: Bayer AG: Revenue (by Segment), 2016-2018
  • Figure 10.16: Bayer Inc: Revenue (by Region), 2016-2018
  • Figure 10.17: Bayer AG: R&D Expenditure, 2016-2018
  • Figure 10.18: Bayer AG: SWOT Analysis
  • Figure 10.19: Biogen Inc: Overall Financials, 2016-2018
  • Figure 10.20: Biogen Inc.: Revenue (by Region), 2016-2018
  • Figure 10.21: Biogen Inc.: R&D Expenditure, 2016-2018
  • Figure 10.22: Biogen Inc: SWOT Analysis
  • Figure 10.23: Eli Lilly and Company: Overall Financials, 2016-2018
  • Figure 10.24: Eli Lilly and Company: Revenue (by Segment), 2016-2018
  • Figure 10.25: Eli Lilly and Company: Revenue (by Region), 2016-2018
  • Figure 10.26: Eli Lilly and Company: R&D Expenditure, 2016-2018
  • Figure 10.27: Eli Lilly and Company: SWOT Analysis
  • Figure 10.28: Evidation Health, Inc.: Product Portfolio for the Global Digital Biomarkers Market
  • Figure 10.29: Evidation Health, Inc: SWOT Analysis
  • Figure 10.30: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
  • Figure 10.31: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
  • Figure 10.32: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
  • Figure 10.33: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
  • Figure 10.34: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 10.35: Fitbit, Inc: Product Portfolio for Global Digital Biomarkers Market
  • Figure 10.36: Fitbit Inc.: Overall Financials, 2016-2018
  • Figure 10.37: Fitbit Inc.: Revenue (by Region), 2016-2018
  • Figure 10.38: Fitbit, Inc.: R&D Expenditure, 2016-2018
  • Figure 10.39: Fitbit Inc.: SWOT Analysis
  • Figure 10.40: GlaxoSmithKline Plc: Overall Financials, 2016-2018
  • Figure 10.41: GlaxoSmithKline Plc: Revenue (by Business Segments), 2016-2018
  • Figure 10.42: GlaxoSmithKline: Revenue (by Region), 2016-2018
  • Figure 10.43: GlaxoSmithKline Plc: R&D Expenditure, 2016-2018
  • Figure 10.44: GlaxoSmithKlin Plc SWOT Analysis
  • Figure 10.45: Human API: Product Portfolio for the Global Digital Biomarkers Market
  • Figure 10.46: Human API: SWOT Analysis
  • Figure 10.47: Happify Health: Product Portfolio for the Global Digital Biomarkers Market
  • Figure 10.48: Happify: SWOT Analysis
  • Figure 10.49: IXICO Plc: Product Portfolio for Global Digital Biomarkers Market
  • Figure 10.50: IXICO plc: Overall Financials, 2016-2018
  • Figure 10.51: IXICO plc: Revenue (by Region), 2016-2018
  • Figure 10.52: IXICO plc: R&D Expenditure, 2016-2018
  • Figure 10.53: IXICO plc: SWOT Analysis
  • Figure 10.54: Koninklijke Philips N.V.: Product Portfolio for the Global Digital Biomarkers Market
  • Figure 10.55: Koninklijke Philips N.V.: Overall Financials ,2016-2018
  • Figure 10.56: Koninklijke Philips N.V.: Revenue (by Segment) ,2016-2018
  • Figure 10.57: Koninklijke Philips N.V.: Revenue (by Region), 2016-2018
  • Figure 10.58: Koninklijke Philips N.V.: R&D Expenditure, 2016-2018
  • Figure 10.59: Koninklije Philips N.V.: SWOT Analysis
  • Figure 10.60: Medopad Ltd: Product Portfolio for the Global Digital Biomarkers Market
  • Figure 10.61: Medopad Ltd: SWOT Analysis
  • Figure 10.62: Mindstrong Health: Product Portfolio for the Global Digital Biomarkers Market
  • Figure 9.63: Mindstrong Health: SWOT Analysis
  • Figure 10.64: Neurotrack Technologies, Inc: Product Portfolio for Global Digital Biomarkers Market
  • Figure 10.65: Neurotrack Technologies, Inc: SWOT Analysis
  • Figure 10.66: Novartis International AG: Overall Financials, 2016-2018
  • Figure 10.67: Novartis AG: Revenue (by Segment), 2016-2018
  • Figure 10.68: Novartis AG: Revenue (by Region), 2016-2018
  • Figure 10.69: Novartis International AG, R&D Expenditure, 2016-2018
  • Figure 10.70: Novartis International AG: SWOT Analysis
  • Figure 10.71: Orikami: SWOT Analysis
  • Figure 10.72: Pfizer, Inc: Overall Financials, 2016-2018
  • Figure 10.73: Pfizer Inc: Revenue (by Segment), 2016-2018
  • Figure 10.74: Pfizer Inc: Revenue (by Region), 2016-2018
  • Figure 10.75: Pfizer Inc.: R&D Expenditure, 2016-2018
  • Figure 10.76: Pfizer Inc.: SWOT Analysis
  • Figure 10.77: Quanterix Corporation: Product Portfolio for Global Digital Biomarkers Market
  • Figure 10.78: Quanterix Corporation: Overall Financials, 2015-2017
  • Figure 10.79: Quanterix Corporation: Revenue (by Region), 2015-2017
  • Figure 10.80: Quanterix Corporation: R&D Expenditure, 2015-2017
  • Figure 10.81: Quanterix Corporation: SWOT Analysis
  • Figure 10.82: Sanofi S.A.: Overall Financials, 2016-2018
  • Figure 10.83: Sanofi: S.A. Revenue (by Business Segments), 2016-2018
  • Figure 10.84: Sanofi S.A.: Revenue (by Region), 2016-2018
  • Figure 10.85: Sanofi S.A.: R&D Expenditure 2016-2018
  • Figure 10.86: Sanofi S.A.: SWOT Analysis
  • Figure 10.87: The Takeda Pharmaceuticals Company Limited: Overall Financials, 2016-2018
  • Figure 10.88: The Takeda Pharmaceuticals Company Limited: Revenue (by Region), 2016-2018
  • Figure 10.89: The Takeda Pharmaceuticals Company Limited: R&D Expenditure, 2016-2018
  • Figure 10.90: The Takeda Pharmaceuticals Company Limited: SWOT Analysis
  • Figure 10.91: Verily Life Sciences: SWOT Analysis
  • Figure 10.92: Cambridge Cognition Plc: Product Portfolio for the Global Digital Biomarkers Market
  • Figure 10.93: MC10 Inc: Product Portfolio for Global Digital Biomarkers Market